Key points are not available for this paper at this time.
The aim of this study was to report safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) over 36 weeks in the ongoing FOREST-HCM trial.
Masri et al. (Thu,) studied this question.